CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE TO COMPLETE YOUR REGISTRATION TO JOIN US IN SAN DIEGO, CA.

CAN’T MAKE IT TO SAN DIEGO? CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE AND SELECT THE LIVE STREAMING OPTION TO PARTICIPATE VIRTUALLY.

Saturday, April 6, 2024
Buffet Dinner: 6:30 PM – 7:00 PM PT
Symposium: 7:00 PM – 8:45 PM PT

LIVE / LIVE VIRTUAL SYMPOSIUM

Marriott Marquis San Diego Marina
Meeting Room: Pacific Ballroom 21-26
333 West Harbor Drive
San Diego, CA, 92101

Faculty

Petros Grivas, MD, PhD
Professor, Division of Hematology Oncology, Dept of Medicine 
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
UW Medicine
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA

Paolo Tarantino, MD
Advanced Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Helena A. Yu, MD
Research Director, Thoracic Oncology Service
Associate Attending 
Memorial Sloan Kettering Cancer Center
New York, NY

Target Audience 

This activity has been designed to address the educational needs of clinicians involved in the treatment of patients with or at risk for advanced solid tumors, including oncologists, pathologists, pulmonologists, and clinical investigators.
 

Educational Provider

This activity is provided by Paradigm Medical Communications, LLC.  

This symposium is not an official program of the American Association for Cancer Research Annual Meeting.
 

Supporter Acknowledgment 

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Program Overview

Although antibody-drug conjugates (ADCs) are available for oncology care, the field of new and emerging novel ADCs is expanding rapidly. Many are in various stages of development for treatment of advanced solid tumors, and even though their general mechanisms are similar, the specific targets and rationales underlying each agent differ, making it challenging for oncology clinicians to remain up to date on development status, clinical trial data, and any new or potential approvals. This activity will highlight expert insights on new and emerging novel ADCs to enable clinicians to incorporate these agents into patient care in the clinical trial setting or once they are approved.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Outline the rationale for developing ADCs against novel targets with regard to their mechanisms of action and the pathophysiology of advanced solid tumors
• Describe the latest clinical trial data for new and emerging ADCs, including efficacy data and status of ongoing studies
• Review the safety profiles of new and emerging ADCs based on the latest clinical trial data

Agenda

6:30 PM – 7:00 PM PT    Registration and Complimentary Buffet Dinner 
7:00 PM – 8:45 PM PT    Clinical Program

• Introduction to ADCs
• New and Emerging ADCs for Advanced Solid Tumors
• Emerging ADCs in the Pipeline
• Safety Profiles and Managing Adverse Events (AEs)
• Conclusion and Roundtable Discussion

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

PA Continuing Education 

PAs may claim a maximum of 1.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 

Disclosure of Relevant Financial Relationships 

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. Disclosure information about relevant financial relationships with ineligible companies (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.

CME Inquires

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

Fee Information

There is no fee required for participation in this activity.

Click “Continue” below and then "Register Now" to select between the live and live streaming options. Once registered, you will receive an email confirmation with the event details.

© 2024 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.